Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2010

01-08-2010 | Commentary

Cancer and diabetes: are we ready for prime time?

Authors: U. Smith, E. A. M. Gale

Published in: Diabetologia | Issue 8/2010

Login to get access

Excerpt

From time to time workers in apparently unrelated fields look sideways to discover that others are working on the same problem from a different angle. This happened recently when investigators in diabetes and cancer found that they were exploring much the same territory, a discovery triggered in part by publications in this journal last year [1‐5]. Controversial though some of the reports have proved, the effect has been an explosion of interest in this previously underexplored area. The result has been an increased appreciation of the intimate connection between metabolism, cell growth and turnover, together with new observations that may come to influence clinical management of diabetes. …
Literature
1.
Smith U, Gale EAM (2009) Does diabetes therapy influence the risk of cancer? Diabetologia 52:1699–1708CrossRefPubMed
2.
Hemkens LG, Grouven U, Bender R (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMed
3.
Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdottir S, Steineck G (2009) Insulin glargine use and short-term cancer incidence—a population-based follow-up in Sweden. Diabetologia 52:1745–1754CrossRefPubMed
4.
Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755–1765, Erratum Diabetologia 52: 2469CrossRefPubMed
5.
Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766–1777CrossRefPubMed
6.
Wilson EB, Maher HC (1932) Cancer and tuberculosis with some comments on cancer and other diseases. Am J Cancer 16:227–250
7.
Podolsky S, Marble A (1985) Diverse abnormalities associated with diabetes. In: Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS (eds) Joslin’s diabetes mellitus, 12th edn. Lea and Febiger, Philadelphia
8.
9.
10.
Iliopoulos D, Hirsch HA, Struhl K (2009) An epigenetic switch involving NFkB, Lin 28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139:693–706CrossRefPubMed
11.
Bowker SL, Yasui Y, Veugelers P, Johnson JA (2010) Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. doi:10.​1007/​s00125-010-1750-8 PubMed
12.
Lipscombe LL, Hux JE, Booth GL (2005) Reduced screening mammography among women with diabetes. Arch Intern Med 165:2090–2095CrossRefPubMed
13.
Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764CrossRefPubMed
Metadata
Title
Cancer and diabetes: are we ready for prime time?
Authors
U. Smith
E. A. M. Gale
Publication date
01-08-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1815-8

Other articles of this Issue 8/2010

Diabetologia 8/2010 Go to the issue

Short Communication

Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice

Review

The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence

Article

A family history of type 2 diabetes increases risk factors associated with overfeeding

Article

Effects of the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals

Short Communication

Real-life glycaemic profiles in non-diabetic individuals with low fasting glucose and normal HbA1c: the A1C-Derived Average Glucose (ADAG) study

Article

Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits